Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome

被引:107
作者
Mendizábal, S [1 ]
Zamora, I [1 ]
Berbel, O [1 ]
Sanahuja, MJ [1 ]
Fuentes, J [1 ]
Simon, J [1 ]
机构
[1] Hosp La Fe, Dept Pediat Nephrol, E-46009 Valencia, Spain
关键词
mycophenolate mofetil; nephrotic syndrome; focal segmental glomerulosclerosis; minimal change disease; children; cyclosporine;
D O I
10.1007/s00467-005-1877-x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Attempts to minimize the effects of prolonged steroid use in steroid-dependent nephrotic syndrome (SDNS) and the need to overcome steroid resistance (SRNS) justifies immunosuppressant therapy. We report our experience in a cohort of patients with SD/SRNS during the administration of mycophenolate mofetil (MMF) in a prospective protocol initiated in January 2001. Twenty-six children with idiopathic nephrotic syndrome were included ( 21 steroid dependent and 5 steroid resistant), whose response did not change after sequential treatment with cyclophosphamide (CPM) and cyclosporine (CsA). Histopathologic patterns were: 11 minimal change disease (MCD), 1 diffuse mesangial proliferation (DMP), 13 focal segmental glomerulosclerosis (FSGS) and membranous 1 glomerulonephritis (MGN). The median age of onset of NS was 2.8 years ( range 1.2 - 12.5), and treatment with MMF was performed at a median age of 11.4 years ( range 5 - 17) with an initial dose of 600 mg/ m(2)/ 12 h, adjusted to maintain levels of mycophenolic acid (MPA) at 2.5 - 5 mcg/ml. The planned duration of study to assess treatment efficacy was 6 months. The mean MMF dose required was 624 (SD = 136) mg/ m(2)/ 12 h ( range 415-70), which maintained mean C-0-MPA levels of 2.9 (SD = 1.17) mcg/ml ( range 1.2 - 5.9 mcg/ml). In the five patients with SRNS, only one achieved complete remission. In the patients with SDNS, steroid sparing was achieved in 15 and 9 remained in remission on MMF monotherapy. Withdrawal of MMF resulted in immediate relapse in 47%. In our study, MMF was a useful immunosuppressant due to its fewer undesirable effects and similar efficacy to other drugs used. It appears effective for the maintenance of remission in SDNS patients, with a response similar to that of CsA.
引用
收藏
页码:914 / 919
页数:6
相关论文
共 31 条
[1]  
Alsaran K, 2001, CLIN NEPHROL, V56, P289
[2]   Levamisole therapy in corticosteroid-dependent nephrotic syndrome [J].
Bagga, A ;
Sharma, A ;
Srivastava, RN .
PEDIATRIC NEPHROLOGY, 1997, 11 (04) :415-417
[3]   Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome [J].
Bagga, A ;
Hari, P ;
Moudgil, A ;
Jordan, SC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (06) :1114-1120
[4]   Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome [J].
Bajpai, A ;
Bagga, A ;
Hari, P ;
Dinda, A ;
Srivastava, RN .
PEDIATRIC NEPHROLOGY, 2003, 18 (04) :351-356
[5]   Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome [J].
Barletta, GM ;
Smoyer, WE ;
Bunchman, TE ;
Flynn, JT ;
Kershaw, DB .
PEDIATRIC NEPHROLOGY, 2003, 18 (08) :833-837
[6]  
Bartosh Sharon M., 1999, Journal of the American Society of Nephrology, V10, p95A
[7]   Successful mycophenolate mofetil treatment of glomerular disease [J].
Briggs, WA ;
Choi, MJ ;
Scheel, PJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (02) :213-217
[8]  
BRIGGS WA, 1977, J AM SOC NEPHROL, V8, pA83
[9]   Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil [J].
Chandra, M ;
Susin, M ;
Abitbol, C .
PEDIATRIC NEPHROLOGY, 2000, 14 (03) :224-226
[10]   Mycophenolate mofetil treatment for primary glomerular diseases [J].
Choi, MJ ;
Eustace, JA ;
Gimenez, LF ;
Atta, MG ;
Scheel, PJ ;
Sothinathan, R ;
Briggs, WA .
KIDNEY INTERNATIONAL, 2002, 61 (03) :1098-1114